The prophylactic and pre-emptive use of ganciclovir (GCV) both reduce significantly the incidence of CMV disease after sibling BMT but it is unclear which of these strategies is best for volunteer unrelated donor (VUD) BMT patients. We reviewed 49 consecutive patients, who received a T-depleted VUD BMT (from March 1990 to March 1996) for the treatment of CML in chronic phase, and were CMV seropositive before transplant or had a CMV seropositive donor. Patients were conditioned with cyclophosphamide (120 mg/kg for 2 days) and total body irradiation (13.2-14.4 Gy). Prophylaxis for GVHD was cyclosporin A and methotrexate with ex vivo or in vivo T cell depletion. Twentyseven patients received pre-emptive GCV if CMV infection was detected by short-term culture before day +120 post BMT. Twenty-two patients received prophylactic GCV from engraftment until day +120 post BMT. The probabilities of CMV infection and disease occurring by 1 year post-BMT were greater in the pre-emptive GCV group than in the prophylactic GCV group (73.8% and 64.0% vs 53.1% and 30.0%, respectively; P = 0.04 and 0.07). The incidence of death from CMV disease was similar in both groups (3/12 (25%) vs 3/10 (30%), respectively) and there was no difference in 1 year survival (55.6% vs 54.2%, respectively). New strategies are urgently required for the prevention of CMV disease after T-depleted VUD BMT.
imperative to treat CMV infection before it develops into disease. Fortunately, major advances have been made in this area through two different approaches, both of which reduce CMV-induced morbidity and mortality and each of which has advantages and disadvantages. In the first (preemptive therapy), patients are given GCV when CMV infection is first identified and this is continued for 3-4 months after BMT; the two studies 6, 7 of this policy show that it fails in 12-13% of cases because CMV disease coincides with the first detection of CMV infection and in only one of the two studies was overall survival improved. In the second approach (prophylactic therapy), GCV is given to all patients at risk of CMV disease from engraftment up to 3-4 months after BMT. 8, 9 Such prophylaxis is very effective at reducing the incidence and severity of CMV infections but overall survival is not improved, perhaps because prolonged use of GCV causes neutropenia 8, 9 and hence susceptibility to bacterial infection; 8 the risk of both these complications being higher than in the studies using pre-emptive therapy. 6, 7 The use of prophylactic GCV also has the added disadvantage that some patients will be exposed to the toxic side-effects of GCV although they will never develop either CMV infection or CMV disease. 10 Finally, patients given prophylactic GCV are unable fully to reconstitute the immune response to CMV and are thus at risk of late CMV disease after therapy has been discontinued. 11 Unfortunately, none of the trials described above was designed to take account of possible differences in response between sibling and VUD BMT patients since the majority of subjects received a sibling's bone marrow and the results for the small number who received marrow from a VUD were not distinguished. [6] [7] [8] [9] Such differences are likely to be important since, for example, after T-depleted VUD BMT there is an increased risk of chronic GVHD and infections including CMV. 12 We therefore undertook a retrospective study of the outcome of prophylactic GCV as compared with pre-emptive GCV in patients who received a Tdepleted VUD BMT at the Hammersmith Hospital.
Patients and methods

Patients
We evaluated all patients with CML in chronic phase, who underwent VUD BMT at the Hammersmith Hospital, Lon-don, between March 1990 and March 1996. Patients who were CMV seronegative before BMT and had a CMV seronegative donor were excluded as were those who died before day +29 post transplant. Thus only 49 patients who were CMV seropositive before transplant or who were CMV seronegative but had a CMV seropositive donor were included in the study. All patients received cyclophosphamide (120 mg/kg) and total body irradiation (TBI) (13.2 or 14.4 Gy) as pre-transplant conditioning. GVHD prophylaxis consisted of conventional cyclosporin A/methotrexate therapy 13 and in vivo T cell depletion (Campath-1 from day −4 to day +5 post BMT) (n = 45) or anti-lymphocyte globulin (from day −5 to day +5) (n = 2), or ex vivo T celldepleted marrow (n = 2).
Twenty-seven patients transplanted between March 1990 and August 1993 received pre-emptive GCV (5 mg/kg twice daily i.v. for 14 consecutive days, followed by 5 mg/kg once daily, 5 days per week until day +120) only if CMV was detected, whilst 22 patients transplanted between September 1993 and March 1996 received prophylactic GCV (5 mg/kg/day i.v., 5 days per week) from the time of engraftment until day +120 post BMT. The clinical characteristics of the study population are shown in Table 1 . CMV = human cytomegalovirus; GVHD = graft-versus-host disease; TBI = total body irradiation.
Detection of CMV and definitions of CMV disease and death due to CMV
The DEAFF (detection of early antigen fluorescent foci) 14 and virus isolation were utilised for the detection of CMV. CMV infection was defined as one or more positive results in blood, urine, throat washings or bronchoalveolar lavage. Blood, urine and throat washings were screened weekly for CMV infection from day 24 to day 120 after BMT. Disease caused by CMV was defined as recovery of the virus from a visceral site (lung, gastrointestinal tract) or from bronchoalveolar lavage in patients who had associated signs (eg pulmonary infiltrate) and symptoms consistent with CMV infection. 15 Death was attributed to CMV if at the time of death the virus was detected in bronchoalveolar lavage from a patient with pneumonitis; in one patient CMV was also detected in a lung biopsy and three patients also had a post-mortem examination that confirmed the presence of CMV in the lung.
Statistical methods
Fisher's exact test for categorical data and the Mann-Whitney test for continuous data were used to compare the characteristics of the two groups of patients. Outcome probabilities were calculated by the method of Kaplan and Meier, and compared using the log-rank test. All quoted P values are two-sided, and confidence intervals refer to 95% boundaries.
Results
The two groups of patients (pre-emptive and prophylactic GCV, respectively) were well matched with respect to age, sex, CMV status pre-BMT, incidence of GVHD and donors (Table 1) . With regard to dose of TBI, those patients in the prophylactic GCV group received either 13.2 or 14.4 Gy as opposed to the pre-emptive group who all received 13.2 Gy but no difference was observed when comparing survival and CMV infection in the prophylactic group (data not shown) and a direct comparison between the two groups for outcome and probability could therefore be made.
CMV infection and disease
The proportion of patients with CMV infection was 19/27 in the pre-emptive GCV group vs 10/22 in the prophylactic GCV group, and the median times of onset of CMV infection were 42 days post BMT (range 18-300) and 81 days post BMT (range 26-242), respectively. The probability of CMV infection occurring by 1 year post BMT was greater in the patients eligible to receive pre-emptive GCV if CMV infection was detected as compared with the patients who received prophylactic GCV (73.8% (CI 54-87) vs 53.1% (CI 31-74), respectively; P = 0.04); as shown in Figure 1 CMV infection occurred more frequently within 100 days post BMT in patients eligible for pre-emptive GCV than in the other group of patients in whom a significant proportion of CMV infections occurred after GCV prophylaxis had been discontinued. Similarly, in those patients with CMV infection, the median times of CMV disease post BMT were 65 days for the pre-emptive group (range 39-160) and 130 days for the prophylactic group (range 91-158); the probability of developing CMV disease was increased in the patients eligible for pre-emptive GCV as compared with the patients who received prophylactic GCV (64% and 30% respectively; P = 0.07). However, there was no difference in mortality from CMV disease; in the pre-emptive group three patients died of CMV disease out of a total 12 deaths in the first year post BMT and in the prophylactic group three patients died of CMV disease out of a total 10 deaths (25% vs 30%, respectively). Of the six patients whose deaths were attributed to CMV, one had concurrent infection with parainfluenza type 3 and aspergillus and the others had no identifiable cause of death other than CMV.
When the data for CMV infection and disease were analysed in terms of CMV antibody status of the patient prior to BMT, 17 out of 19 CMV seropositive patients who were eligible for pre-emptive GCV developed CMV infection as compared with nine of 15 patients who received prophylactic GCV (89% and 60%, respectively; P = 0.05). Similarly 10 seropositive patients in the pre-emptive group developed CMV disease vs only three in the prophylactic group (53% and 20%, respectively; P = 0.05). In contrast, of the CMV seronegative patients all of whose donors were CMV seropositive, only two of eight eligible for pre-emptive GCV had CMV infection and disease, while only one of seven who received prophylactic GCV had CMV infection but no disease.
Survival
The probabilities of survival at 1 year post transplant were similar in the pre-emptive and prophylactic GCV groups (55.6% (CI 37-72) and 54.2% (CI 34-73), respectively; P = 0.85) (Figure 2 ). There was no difference between those patients in the pre-emptive or prophylactic GCV groups in terms of death from all viral infections (5/12 (42%) and 5/12 (42%), respectively) or death from nonviral infection (fungal + bacterial) (3/12 (25%) and 4/10 (40%), respectively) ( Table 2) , nor for death from graft failure (1/12 (8.3%) and 1/10 (10%), respectively). 
Discussion
The role of VUD BMT in the management of CML is limited by the substantially increased incidence of GVHD compared with sibling allografts. T cell depletion, which is routine practice at the Hammersmith Hospital for VUD BMT, reduces the incidence and severity of GVHD but is associated with an increased incidence of fatal viral infections, particularly CMV. 12, 16, 17 The aim of the present work was to see if the use of prophylactic GCV is more effective than pre-emptive GCV in improving the outcome after Tdepleted VUD BMT in terms of CMV disease and overall survival. We found that CMV seropositive patients were at high risk of recurrent CMV infection and disease whereas CMV seronegative individuals who received marrow from a CMV seropositive donor were at a much lower risk of primary infection and consequent disease, as previously observed, 1, 18 suggesting that the donor marrow is of limited importance in the transmission of CMV. Thus, almost all CMV seropositive patients in the pre-emptive group received GCV in contrast to a low proportion of the CMV seronegative patients.
Considering the overall results for CMV infection without separating CMV seropositive and seronegative patients, in the pre-emptive GCV patient group CMV infection tended to be detected early after engraftment (median day 42) whereas in the prophylactic group the tendency was for CMV infection to be detected later (median day 81) (Figure 1) , and the timing of CMV disease showed a similar difference between the two groups. These differences were predictable since it has been reported that use of prophylactic GCV postpones the onset of CMV disease, 11 but we had hoped that the prophylactic approach would reduce the likelihood of CMV disease and mortality after T-depleted VUD BMT to an acceptable level; unfortunately this was not the case (probability of CMV disease 30%), a finding confirmed in one other study of adult BMT recipients but using a lower dose of prophylactic GCV. 17 However, preemptive GCV was even less effective (probability of CMV disease 64%), and the outcome was similar for both groups in terms of deaths due to CMV, or other bacterial and fungal infections and in survival at 1 year.
In view of these results, we have now modified our policy 10 at the Hammersmith Hospital in an attempt to reduce the risk of CMV disease after VUD BMT whilst improving overall survival. Firstly, we have changed our method for detection of CMV infection from the DEAFF 14 to detection of CMV antigenaemia; 19, 20 this should greatly improve the detection of CMV infection since the antigenaemia test is more sensitive 19, 20 and will detect breakthrough infection during GCV prophylaxis 21 whereas the DEAFF is especially insensitive in this context. Secondly, the period of monitoring for CMV infection has been extended up to day +180 post transplant so that late CMV disease may be predicted and GCV therapy initiated. Thirdly, we use preemptive GCV therapy for CMV seronegative recipients with a CMV seropositive donor but continue to use GCV prophylaxis for CMV seropositive patients; the rationale was to expose CMV seronegative patients to GCV and its side-effects only after CMV infection had been detected since many such patients would never develop either CMV infection or disease, but to continue with GCV prophylaxis in CMV seropositive patients in whom we found the risk of CMV infection and disease to be extremely high.
In conclusion, there was no evidence for the superiority of the prophylactic vs the pre-emptive GCV regimen after VUD BMT, and in both cases there was a significant incidence of CMV-induced morbidity and mortality. The use of more sensitive tests such as CMV PCR 22 or antigenaemia 19, 20 might have improved the outcome as might the use of short courses of GCV treatment (CMV infection-guided treatment) instead of prolonged GCV therapy (either prophylactic or pre-emptive) with its consequent toxicity. However, a recent study including a preponderance of sibling BMT patients has shown that CMV infection-guided treatment gives the same outcome as prophylactic GCV. 23 Future possible strategies might include alternative methods of GVHD prophylaxis, 24 suppression of CMV infection with foscarnet 25, 26 or a combination of foscarnet and GCV, 27 continuing GCV prophylaxis for longer to prevent late CMV disease, adoptive transfer of CD8 + CMV-specific CTL clones derived from the marrow donor, 28 or enhancing immune reconstitution post BMT by the use of subunit anti-CMV vaccines such as gB or pp65. 29, 30 
